PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

Im, Seock‐Ah; Xu, Binghe; Kim, Sung‐Bae; Chung, Weon Kuu; Park, Yeon Hee; Kim, Min-Hwan; Tseng, Ling‐Ming; Chung, Chi-Feng; Kim, Jee Hyun; Chiu, Joanne Wing Yan; Yamashita, Toshinari; Li, Wei; Lee, Caleb; Nishijima, Soichiro; Hamada, Kyohei; Nishiyama, Yuta; Sato, Masahiro; Cortés, Javier; Iwata, Hiroji

doi:10.1016/j.annonc.2022.05.064

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limitations in this trial include a higher enrolment of patients from Asia versus North America and Europe; however, in a subgroup analysis based on the interim analysis of progression-free survival, efficacy of trastuzumab deruxtecan in patients from Asia was similar to the overall population. 32 The single HR reported for the interim analysis of progression-free survival also has limitations, as the instantaneous HR has built-in selection bias and might change over time; therefore, the average HR depends on the follow-up time. 33 Furthermore, in this second overall survival interim analysis, median overall survival was not reached but future analyses might determine overall survival duration in DESTINY-Breast03.…”

Section: Discussionmentioning

confidence: 99%

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

et al. 2023

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

et al. 2023

Self Cite

View full text Add to dashboard Cite

Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer

Nie

Blair

2023

Targ Oncol

View full text Add to dashboard Cite

show abstract

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Nakayama,

Niikura,

Yamanaka

et al. 2024

Breast Cancer

View full text Add to dashboard Cite

We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer with brain metastases (BM) and/or leptomeningeal disease (ROSET-BM). Median progression-free survival (PFS) was 14.6 months. Median overall survival (OS) was not reached (NR); 24-month OS rate was 56.0%. Subgroup analysis showed that median PFS was 13.2 months in patients with analytical active BM, 17.5 months in patients with leptomeningeal carcinomatosis (LMC), and NR in patients with analytical stable BM (24-month PFS rates in patients with analytical active BM, LMC, and analytical stable BM were 32.7%, 25.1%, and 60.8%, respectively). Median OS was 27.0 months in patients with analytical active BM and NR in patients with LMC or analytical stable BM (24-month OS rates in patients with analytical active BM, LMC, and analytical stable BM were 52.0%, 61.6%, and 71.6%, respectively). The most common adverse event leading to discontinuation of T-DXd was interstitial lung disease (ILD; 23.1%); median ILD onset time among patients who discontinued T-DXd treatment due to ILD was 5.3 months. T-DXd has promising effectiveness in heavily pre-treated HER2+ metastatic breast cancer patients with BM and LMC. The incidence and median onset time of ILD were similar to those of Japanese subgroups in previous studies.

show abstract

PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

Cited by 4 publications

References 0 publications

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Contact Info

Product

Resources

About